Here is a condensed recap of where each compound currently stands: CJC-1295: not FDA-approved
If you are considering weaning off tirzepatide after achieving your weight loss goals, be aware that weight regain can reverse the metabolic improvements that protected against UTIs
(2026) Impact of GLP-1 RA plus Progestin Therapy on Conservative Management of Endometrial Cancer and Endometrial Intraepithelial Neoplasia, SGO 2026 Annual Meeting on Womens Cancer, San Juan, Puerto Rico, April 10-13th 2026
Composition AOD 9604: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Peptide identity and purity assessment via HPLC/LC-MS Assay development and calibration for quantitative analysis Chromatographic method optimization for impurity profiling Stability characterization of a lyophilized peptide under laboratory storage conditions Documentation COA pending third-party verification in progress Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA (HPLC/LC-MS) with verification key Third-party verification link provided per lot (Janoshik) Lyophilized for transit stability
Tirzepatide can increase your heart rate at rest